Literature DB >> 16117980

Effects of dexamethasone in preventing postoperative emetic symptoms after total knee replacement surgery: a prospective, randomized, double-blind, vehicle-controlled trial in adult Japanese patients.

Yoshitaka Fujii1, Masahiro Nakayama.   

Abstract

BACKGROUND: Postoperative emetic symptoms (nausea, retching, and vomiting) are common following total joint replacement, with an incidence as high as 83% when no prophylactic antiemetic is provided. However, most antiemetics currently used in Japan, such as antihistamines (eg, hydroxyzine), butyrophenones (eg, droperidol), and dopamine receptor antagonists (eg, metoclopramide), have been associated with adverse effects (AEs), such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations, and extrapyramidal symptoms.
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of 3 doses of intravenous dexamethasone monotherapy versus vehicle in preventing emetic symptoms after total knee replacement performed under combined general and epidural anesthesia.
METHODS: This prospective, randomized, double-blind, vehicle-controlled trial was conducted at the Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan. Adult Japanese patients scheduled to undergo total knee replacement were eligible. Patients were randomly assigned to 1 of 4 treatment groups: dexamethasone 4, 8, or 16 mg, or vehicle (control). Patients received combination anesthesia with sevoflurane and nitrous oxide in pure oxygen (general) and lidocaine (epidural). Study drugs were administered intravenously after the completion of surgery. An investigator blinded to treatment assignment monitored patients for emetic symptoms for 24 hours after the patient awoke. Patients rated their satisfaction with the study drug using a linear, 11-point scale (0 = complete satisfaction to 10 = complete dissatisfaction). Tolerability was assessed by the study investigator using spontaneous reporting and patient interview.
RESULTS: A total of 80 patients were enrolled (58 women, 22 men; mean [SD] age, 59 [10] years; mean [SD] height, 154 [7] cm; mean [SD] body weight, 55 [7] kg; 20 patients per treatment group). The demographic, clinical, and surgical data were comparable between the 4 treatment groups. The rates of emesis-free patients were 35% (7 patients), 70% (14), and 75% (15) with dexamethasone 4, 8, and 16 mg, respectively, compared with 30% (6) with vehicle (P = NS, 0.013, and 0.005, respectively). Median (range) patient satisfaction scores were significantly higher in the groups receiving dexamethasone 8 and 16 mg (both, 0.0 [0-9]) compared with controls (6.0 [0-10]) (P = 0.013 and 0.008, respectively). This effect was not found with the 4-mg dose. No clinically serious AEs attributed to the study drug were observed in any of the 4 treatment groups.
CONCLUSIONS: In this study of a small, select group of adult Japanese patients undergoing total knee replacement, the rates of emesis-free patients were higher with dexamethasone 8 and 16 mg compared with vehicle 24 hours after anesthesia induction. This effect was not found with the 4-mg dose. All treatments were well tolerated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117980     DOI: 10.1016/j.clinthera.2005.05.011

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  14 in total

Review 1.  Perioperative systemic glucocorticoids in total hip and knee arthroplasty: A systematic review of outcomes.

Authors:  Jeffrey Hartman; Vickas Khanna; Anthony Habib; Forough Farrokhyar; Muzammil Memon; Anthony Adili
Journal:  J Orthop       Date:  2017-04-12

2.  Two doses of low-dose perioperative dexamethasone improve the clinical outcome after total knee arthroplasty: a randomized controlled study.

Authors:  Bin Xu; Jun Ma; Qiang Huang; Ze-Yu Huang; Shao-Yun Zhang; Fu-Xing Pei
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-05-04       Impact factor: 4.342

3.  Perioperative dexamethasone does not affect functional outcome in total hip arthroplasty.

Authors:  Stephane G Bergeron; Kenneth J Kardash; Olga L Huk; David J Zukor; John Antoniou
Journal:  Clin Orthop Relat Res       Date:  2009-02-18       Impact factor: 4.176

4.  Preemptive low-dose dexamethasone reduces postoperative emesis and pain after TKA: a randomized controlled study.

Authors:  In Jun Koh; Chong Bum Chang; Jung Ha Lee; Young-Tae Jeon; Tae Kyun Kim
Journal:  Clin Orthop Relat Res       Date:  2013-05-04       Impact factor: 4.176

Review 5.  A systematic review and meta-analysis of intravenous glucocorticoids for acute pain following total hip arthroplasty.

Authors:  Xiuhua Li; Zheng Sun; Chengbing Han; Liangliang He; Baoguo Wang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 6.  Perioperative systemic steroid for rapid recovery in total knee and hip arthroplasty: a systematic review and meta-analysis of randomized trials.

Authors:  Chen Yue; Rong Wei; Youwen Liu
Journal:  J Orthop Surg Res       Date:  2017-06-27       Impact factor: 2.359

7.  Low-dose dexamethasone during arthroplasty: What do we know about the risks?

Authors:  Jessica T Wegener; Tim Kraal; Markus F Stevens; Markus W Hollmann; Gino M M J Kerkhoffs; Daniël Haverkamp
Journal:  EFORT Open Rev       Date:  2017-03-13

Review 8.  Preoperative intravenous glucocorticoids can decrease acute pain and postoperative nausea and vomiting after total hip arthroplasty: A PRISMA-compliant meta-analysis.

Authors:  Qing Yang; Zhi Zhang; Wenqi Xin; Aixiang Li
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

9.  Preoperative intravenous glucocorticoids can reduce postoperative acute pain following total knee arthroplasty: A meta-analysis.

Authors:  Xiangcheng Liu; Jinglong Liu; Ganghe Sun
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 10.  Can intravenous steroid administration reduce postoperative pain scores following total knee arthroplasty?: A meta-analysis.

Authors:  Li-Zhi Xing; Li Li; Lan-Ju Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.